These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11911562)

  • 1. Effectiveness of low doses of simvastatin versus atorvastatin: resolving conflicting evidence.
    Chong C; Kelly S; Bradley M
    Clin Ther; 2002 Feb; 24(2):325-8. PubMed ID: 11911562
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of simvastatin and atorvastatin in hypercholesterolemic patients.
    Bolaman Z; Kadikoylu G
    Clin Ther; 2003 Oct; 25(10):2631-3. PubMed ID: 14667963
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels.
    Kastelein JJ; Isaacsohn JL; Ose L; Hunninghake DB; Frohlich J; Davidson MH; Habib R; Dujovne CA; Crouse JR; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB
    Am J Cardiol; 2000 Jul; 86(2):221-3. PubMed ID: 10913488
    [No Abstract]   [Full Text] [Related]  

  • 4. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
    Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
    Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atorvastatin versus simvastatin.
    Calder RA
    Am J Cardiol; 1997 Dec; 80(12):1646. PubMed ID: 9416964
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of low doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol levels in patients with hypercholesterolemia.
    Branchi A; Fiorenza AM; Torri A; Muzio F; Berra C; Colombo E; Dalla Valle E; Rovellini A; Sommariva D
    Clin Ther; 2001 Jun; 23(6):851-7. PubMed ID: 11440285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome.
    Hunninghake DB; Ballantyne CM; Maccubbin DL; Shah AK; Gumbiner B; Mitchel YB
    Clin Ther; 2003 Jun; 25(6):1670-86. PubMed ID: 12860491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
    Rader DJ; Davidson MH; Caplan RJ; Pears JS
    Am J Cardiol; 2003 Mar; 91(5A):20C-23C; discussion 23C-24C. PubMed ID: 12646340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
    Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
    J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia.
    Wierzbicki AS; Lumb PJ; Chik G; Crook MA
    Am J Cardiol; 2000 Sep; 86(5):547-9, A9. PubMed ID: 11009276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of atorvastatin compared with simvastatin in patients with hypercholesterolemia.
    Farnier M; Portal JJ; Maigret P
    J Cardiovasc Pharmacol Ther; 2000 Jan; 5(1):27-32. PubMed ID: 10687671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of heterozygous familial hypercholesterolemia: atorvastatin vs simvastatin.
    Bo M; Nicolello MT; Fiandra U; Mercadante G; Piliego T; Fabris F
    Nutr Metab Cardiovasc Dis; 2001 Feb; 11(1):17-24. PubMed ID: 11383320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of atherosclerosis progression.
    Young JH
    Lancet; 2001 Jul; 358(9278):328-9. PubMed ID: 11501528
    [No Abstract]   [Full Text] [Related]  

  • 14. Statin effects on LDL and HDL cholesterol in South Asian and white populations.
    Gupta M; Braga MF; Teoh H; Tsigoulis M; Verma S
    J Clin Pharmacol; 2009 Jul; 49(7):831-7. PubMed ID: 19398601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No difference in plasma fibrinogen levels between CAPD patients taking atorvastatin and simvastatin.
    Singhal MK; Bhaskaran S; Szabo T; La Rosa R
    Perit Dial Int; 1999; 19(1):89-91. PubMed ID: 10201354
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
    Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
    Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease.
    Karalis DG; Ross AM; Vacari RM; Zarren H; Scott R
    Am J Cardiol; 2002 Mar; 89(6):667-71. PubMed ID: 11897207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S; Schuster H; Barter P; Watkins C; Kallend D;
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
    Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR;
    Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.